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journal homepage: ht tp: / /www.jnimonline.com/EditorialThe present edition focusses on novel concepts and contro-
versies surrounding long chain n-3 polyunsaturated fatty acids
(LCn-3PUFA).
Despite the general agreement about the health beneﬁts of LCn-
3PUFA, some controversies have been raised, particularly with
regards to the possible oxidative metabolites that may be present
in the marine oils. Marine oils constitute an extremely complex di-
etary intervention for a number of reasons: i) the many chemical
compounds they contain; ii) the many biological processes affected
by LCn-3PUFA; iii) their tendency to deteriorate and form poten-
tially toxic primary and secondary oxidation products; and iv) inac-
curacy in the labelling of consumer products. The large body of
research that has been conductedworld-wide, especially on cardio-
vascular health, could be difﬁcult to interpret for making ﬁnal rec-
ommendations due to the variation in the oils used, doses used as
well as possible changes in the oil composition during storage.
Although the original hypothesis of the link between LCn-3PUFA
and CVD protection was based on a high LCn-3PUFA containing
diet (high in marine fat) the majority of clinical trials since have
focussed on EPA and DHA supplementation, and results of repeated
meta-analyses have not shown conclusive evidence in support of
their beneﬁcial health effects. Further attention is given to factors
that can impact on the efﬁcacy of LCn-3PUFA such as source (plant
vs marine vs supplements (algal vs marine)), stability of product,
dose, trial duration, ratio of EPA:DHA, and ratio of n-6:n-3PUFA in
the diet.
Emerging evidence suggests that LCn-3PUFA and their metabo-
lites improvematernal and neonatal health outcomes bymodifying
gestational length, and reducing the recurrence of pre-term deliv-
ery. Prolonged gestation usually results in a larger baby which
could complicate birth and larger babies could be prone to develop
health issues in later life such as obesity and diabetes. Interestingly
the stages of pregnancy are characterised by different cytokines,
being pro-inﬂammatory in the earlier stages to regulate pregnancy
establishment while becoming anti-inﬂammatory in the mid-stage
to support pregnancy maintenance and optimal foetal growth. The
LCn-3PUFA present during pregnancy will affect the proﬁles and
thus there are indications that the speciﬁc doses of n-6 and LCn-
3PUFA in the diet should be adapted as per the status of the preg-
nancy. In order to further investigate the beneﬁts and contribution
of LCn-3PUFA during and after pregnancy, a meta-analysis and sys-
tematic review of randomized and semi-randomized controlled tri-
als was conducted on breast-fed or formulae fed babies. This meta-
analysis shows that LCn-3PUFA supplementation in infants deliv-
ered either maternally or in formula/directly, does not improve
visual acuity, language development, or cognition. The analyseshttp://dx.doi.org/10.1016/j.jnim.2016.07.001
2352-3859/© 2016 Published by Elsevier Inc. This is an open access article under the CCalso showed that LCn-3PUFA supplements affect infant immune
system development and reduce pro-inﬂammatory responses in
the supplemented breastfed and fortiﬁed formula fed/directly sup-
plemented infants. Overall, the evidence does not support the
continued supplementation of infant formula with LCn-3PUFA
and more studies are required to understand the effects of these
on infant immunity. In contrast, LCn-3PUFA are critical for the
normal growth and development of preterm infants. Due to their
immunological immaturity, preterm infants are particularly sensi-
tive to diseases with an inﬂammatory aetiology in the early post-
natal period. This makes DHA supplementation an attractive
therapy immediately after birth to combat neonatal inﬂammation.
However, themechanisms of action of DHA and other LCn-3PUFA in
preterm infants are not clear, and further research should be done
to clarify these further.
In older adults, low grade inﬂammation is associated with
several diseases such as obesity, osteoporosis and metabolic syn-
drome. As result, elevated levels of pro-inﬂammatory cytokines
may increase the risk of development of a spectrum of inﬂamma-
tory diseases and has been shown to predict mortality. LCn-
3PUFA are anti-inﬂammatory and should therefore be associated
with measured levels of cytokines in individuals. Red cell mem-
brane LCn-3PUFA composition was, after multivariate adjustments,
inversely associated with CRP and monocyte cell counts and total
LCn-3PUFA were inversely related to white blood cells. However
no association between ﬁbrinogen and omega-3 index (O3I) or total
LCn-3PUFAwas detected. This study demonstrated a negative asso-
ciation between O3I and biomarkers of inﬂammation in an older
cohort. In addition, in older adults, an inverse association was
detected between the O3I and anthropometric measures. Stratiﬁca-
tion of data by sex indicated that these associations were sex-
speciﬁc. Females displayed an inverse association between the
O3I, BMI and waist circumference. In contrast, no signiﬁcant asso-
ciation between the O3I and anthropometric measures was
detected in males. In the same cohort, when indicators of non-
alcoholic fatty liver disease (NAFLD) were assessed together with
LCn-3PUFA status, a signiﬁcant inverse relationship was found be-
tween O3I and NAFLD. This relationship was gender speciﬁc with
women, but not men. The ﬁndings of these two studies support
the proposal for sex-stratiﬁed LCn-3PUFA intervention trials in
this high-risk age group.
Three quite diverse submissions to this special edition discuss
the role of LCn-3PUFA in depression, during cancer therapy and in
patients with chronic obstructive pulmonary disease (COPD). The
latter is characterised by airway inﬂammation, and statins, LCn-
3PUFA and lycopene have been shown to reduce inﬂammation. InBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
M. Kruger / Journal of Nutrition & Intermediary Metabolism 5 (2016) 1e22a 12 week study on patients with COPD, rosuvastatin, n-3PUFA and
lycopene had some anti-inﬂammatory effects systemically, but
rosuvastatin may have increased airway neutrophils, which would
be undesirable in COPD patients, warranting further investigation.
Cross-national and cross-sectional data suggest that greater
habitual intake of preformed EPAþ DHA is associated with reduced
risk for developing depressive symptoms and major depressive dis-
order (MDD). Interestingly, low LCn-3PUFA biostatus is associated
with an increased risk for depressive symptoms in part by augment-
ing pro-inﬂammatory responsivity. These ﬁndings provide a strong
foundation in support of dietary LCn-3PUFA deﬁciency as a modiﬁ-
able risk factor for MDD. Future directions including strategies to
translate this evidence into routine clinical screening and treatment
algorithms are discussed in the review by Prof McNamara. The
concept of supplementing LCn-3PUFA during chemotherapy forcancer is evaluated in a paper by Dr Mazurak. The latter seems to
result in less side effects, lower toxicity and less hospitalisations.
In a review barriers are identiﬁed to understanding mechanisms
of host protection and considerations for future clinical trials are
presented. Further work is also proposed to investigate potential
mechanisms by which LCn-3PUFA supplementation can improve
chemotherapy tolerability and ultimately patient outcomes.Marlena Kruger, Professor
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